{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:41:09Z","timestamp":1776094869574,"version":"3.50.1"},"reference-count":61,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AstraZeneca"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/13696998.2025.2609507","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:41:18Z","timestamp":1776091278000},"page":"1059-1075","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1151-9903","authenticated-orcid":false,"given":"Gilberto de Lima","family":"Lopes","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center","place":["Miami, US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Freeman","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Procter","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4617-5610","authenticated-orcid":false,"given":"Elysia","family":"Upton","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Cambridge, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-9452","authenticated-orcid":false,"given":"Pritesh","family":"Karia","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0633-6211","authenticated-orcid":false,"given":"Yanique","family":"Rattigan-Brown","sequence":"additional","affiliation":[{"name":"AstraZeneca","place":["Gaithersburg, US"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Hearmon","sequence":"additional","affiliation":[{"name":"Costello Medical","place":["London, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1605-4719","authenticated-orcid":false,"given":"Jorge J.","family":"Nieva","sequence":"additional","affiliation":[{"name":"Norris Cancer Center, University of Southern California","place":["Los Angeles, US"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"e_1_3_5_2_1","unstructured":"International Agency for Research on Cancer (IARC). 2022. Cancer Today. World Factsheet. [cited 2026 January]. Available from: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"e_1_3_5_3_1","unstructured":"American Cancer Society (ACS). Cancer facts and figures 2025. 2025. [cited 2026 January]. Available from: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4932"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v12.i4.217"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108412"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70024"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/LCTT.S119644"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.07.014"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00272-5"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00208"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1709-0"},{"key":"e_1_3_5_15_1","unstructured":"Food and Drug Administration (FDA). TAGRISSO (osimertinib) USPI. 2024. [cited 2026 January]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208065s033lbl.pdf."},{"key":"e_1_3_5_16_1","unstructured":"Food and Drug Administration (FDA). RYBREVANT (amivantamab-vmjw) USPI. 2025. [cited 2026 January]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761210s007lbl.pdf."},{"key":"e_1_3_5_17_1","unstructured":"Food and Drug Administration (FDA). LAZCLUZE (lazertinib) USPI. 2024. [cited 2026 January]. Available from: https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/LAZCLUZE-pi.pdf."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01061"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510308"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403614"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503001"},{"key":"e_1_3_5_23_1","unstructured":"Subcutaneous amivantamab biologics license application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer. 2024. [Internet]."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01001"},{"key":"e_1_3_5_25_1","unstructured":"American Medical Association. Trends in health care spending. 2025. [cited 2025 July 22]. Available from: https:\/\/www.ama-assn.org\/about\/ama-research\/trends-health-care-spending."},{"key":"e_1_3_5_26_1","unstructured":"Microsoft Corporation. Microsoft Excel. 2025. 2503. Available from: https:\/\/www.microsoft.com\/en-us\/microsoft-365\/excel."},{"key":"e_1_3_5_27_1","unstructured":"Analysis USBoE. Table 2.3.4. Price indexes for personal consumption expenditures by major type of product: U.S. Bureau of Economic Analysis; 2025 [January 19 2026]. Available from https:\/\/www.bea.gov\/itable\/national-gdp-and-personal-income."},{"key":"e_1_3_5_28_1","unstructured":"RED BOOK. [Internet]. 2026. [cited January 2026]. Available from: https:\/\/www.micromedexsolutions.com\/home\/dispatch."},{"key":"e_1_3_5_29_1","unstructured":"RED BOOK. 2025. [Internet]. [cited December 2025]. Available from: https:\/\/www.micromedexsolutions.com\/home\/dispatch."},{"key":"e_1_3_5_30_1","unstructured":"IQVIA. Longitudinal access and adjudication data. 2023."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.1022"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001958"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2022.5422"},{"key":"e_1_3_5_34_1","unstructured":"Health Economics Research Center. Determining the cost of pharmaceuticals for a cost-effectiveness analysis. 2024."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-011-0928-2"},{"key":"e_1_3_5_36_1","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal: osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]. 2024. Available from: https:\/\/www.nice.org.uk\/guidance\/ta1060\/documents\/committee-papers."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000146"},{"key":"e_1_3_5_38_1","unstructured":"Food and Drug Administration (FDA). Carboplatin USPI. 2012. [cited 2026 January]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/077139Orig1s016lbl.pdf."},{"key":"e_1_3_5_39_1","unstructured":"Food and Drug Administration (FDA). Pemetrexed USPI. 2022. [cited 2026 January]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/214657s000lbl.pdf."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198710223171717"},{"key":"e_1_3_5_41_1","unstructured":"Johnson & Johnson. Rybrevant faspro (amivantamab and hyaluronidase-lpuj) USPI: Johnson & Johnson. 2025. [cited 2026 January]. Available from: https:\/\/www.jnjlabels.com\/package-insert\/product-monograph\/prescribing-information\/RYBREVANT\u00b1Faspro-pi.pdf."},{"key":"e_1_3_5_42_1","unstructured":"Johnson & Johnson. Dosage & administration for rybrevant + lazcluze (lazertinib). 2025. [cited 2026 January]. Available from: https:\/\/www.rybrevanthcp.com\/ryb-laz\/#."},{"key":"e_1_3_5_43_1","unstructured":"Physician Fee Schedule. 2025. [Internet]. Available from: https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_5_44_1","article-title":"How much more than medicare do private insurers pay?","author":"Lopez E","year":"2020","unstructured":"Lopez E, Neuman T, Jacobson G, et al. How much more than medicare do private insurers pay? A Review of the Literature. 2020; Kaiser Family Foundation. Available from: https:\/\/www.kff.org\/medicare\/how-much-more-than-medicare-do-private-insurers-pay-a-review-of-the-literature\/.","journal-title":"A Review of the Literature"},{"key":"e_1_3_5_45_1","first-page":"1517","volume-title":"J Thorac Oncol","author":"Cho BC","year":"2025","unstructured":"Cho BC, Li W, Spira AI, et al. Enhanced versus standard dermatologic management with amivantamab-lazertinib in EGFR-mutated advanced NSCLC: The COCOON global randomized controlled trial. J Thorac Oncol. 2025;20:1517\u20131530."},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102589"},{"key":"e_1_3_5_47_1","unstructured":"Johnson & Johnson. FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month 2026. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/fda-approves-rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-as-the-only-egfr-targeted-therapy-that-can-be-administered-once-a-month."},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.01.018"},{"key":"e_1_3_5_49_1","volume-title":"Academy of Managed Care Pharmacy (AMCP) Nexus","author":"Vadagam P","year":"2024","unstructured":"Vadagam P, Lin I, Musci R, et al. Modeled costs of adverse event management in treatment na\u00efve EGFR NSCLC patients with exon 19 deletion or exon 21 L858R mutations treated with amivantamab plus lazertinib, osimertinib plus chemotherapy, or osimertinib alone. Academy of Managed Care Pharmacy (AMCP) Nexus. Nevada, USA Las Vegas; 2024."},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta17310"},{"key":"e_1_3_5_51_1","unstructured":"Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule 2025. Available from: https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/clinical-laboratory-fee-schedule-clfs."},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1885418"},{"key":"e_1_3_5_53_1","unstructured":"Doherty K. High-risk features could guide treatment intensification in first-line EGFR-mutated NSCLC: oncLive. 2025. Available from: https:\/\/www.onclive.com\/view\/high-risk-features-could-guide-treatment-intensification-in-first-line-egfr-mutated-nsclc."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.03.571"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2309838"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1467918"},{"key":"e_1_3_5_57_1","volume-title":"IASLC 2025 world conference on lung cancer","author":"Planchard C","year":"2025","unstructured":"Planchard C, J\u00e4nne PA, Kobayashi K. editor First-line osimertinib\u2009+\u2009chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. IASLC 2025 world conference on lung cancer; 2025. September 6-9. Barcelona, Spain."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.02.003"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020259"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2024.100610"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473822"},{"key":"e_1_3_5_62_1","article-title":"Preventing Infusion-related Reactions with Intravenous Amivantamab: Updated Results From SKIPPirr, a Phase 2 Study","author":"Paz-Ares L","year":"2024","unstructured":"Paz-Ares L, Spira AI, Han J-Y, et al., editors. Preventing Infusion-related Reactions with Intravenous Amivantamab: Updated Results From SKIPPirr, a Phase 2 Study. European Society for Medical Oncology (ESMO); 2024; Barcelona, Spain.","journal-title":"European Society for Medical Oncology (ESMO)"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2609507","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T14:41:33Z","timestamp":1776091293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2609507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2609507"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2609507","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}